Docking studies were conducted to propose a potential therapeutic strategy aimed at mitigating the increased expression of PIK3R1, thereby reducing inflammation severity in ARVC individuals. Here, PIK3R1 is linked to Arrhythmogenic right ventricular dysplasia.